PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 2, 2015Journal of Clinical Oncology429 citationsOpen Access

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

SBStefan BielackSSSigbjørn SmelandJWJeremy Whelan

Key Points

Key points are not available for this paper at this time.

Abstract

At the preplanned analysis time, MAP plus IFN-α-2b was not statistically different from MAP alone. A considerable proportion of patients never started IFN-α-2b or stopped prematurely. Long-term follow-up for events and survival continues.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Bielack et al. (2015) studied this question.

synapsesocial.com/papers/69db23c778a3e0e288684fd3https://doi.org/10.1200/jco.2014.60.0734
Ask AI
Helpful
Bookmark
Share
View Full Paper